| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441834 | European Journal of Cancer | 2015 | 7 Pages |
Abstract
PHARE confirm that the incidence of cardiac end-points remains low and mostly reversible after trastuzumab. Identification at baseline of cardiac risk categories of patients should be of interest to provide an optimal adaptation of adjuvant modalities and a shorter duration might be an option.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Xavier Pivot, Thomas Suter, Jean Marc Nabholtz, Jean Yves Pierga, Marc Espie, Alain Lortholary, David Khayat, Iris Pauporte, Gilles Romieu, Andrew Kramar, Pierre Fumoleau,